Similar articles for PMID: 11124283

Year	Number of Results
1966	2
1967	1
1975	2
1978	1
1980	16
1981	9
1982	3
1983	5
1984	8
1985	2
1987	3
1988	9
1989	3
1990	16
1991	18
1992	15
1993	22
1994	18
1995	22
1996	23
1997	19
1998	16
1999	9
2000	13
2001	10
2002	13
2003	7
2004	8
2005	10
2006	8
2007	7
2008	7
2009	7
2010	6
2011	7
2012	8
2013	6
2014	9
2015	8
2016	9
2017	3
2018	6
2019	5
2020	7
2021	7
2022	8
2023	4
2024	3

1

Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.

Schiff MH, Whelton A. Schiff MH, et al. Semin Arthritis Rheum. 2000 Dec;30(3):196-208. doi: 10.1053/sarh.2000.16641. Semin Arthritis Rheum. 2000. PMID: 11124283 Review.

2

DMARDs in the treatment of rheumatoid arthritis: current agents and future developments.

Simon LS. Simon LS. Int J Clin Pract. 2000 May;54(4):243-9. Int J Clin Pract. 2000. PMID: 10912314 Review.

3

An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.

van Roon EN, van den Bemt PM, Jansen TL, Houtman NM, van de Laar MA, Brouwers JR. van Roon EN, et al. Clin Ther. 2009 Aug;31(8):1737-46. doi: 10.1016/j.clinthera.2009.08.009. Clin Ther. 2009. PMID: 19808132 Review.

4

Remission in rheumatoid arthritis: wishful thinking or clinical reality?

Sesin CA, Bingham CO 3rd. Sesin CA, et al. Semin Arthritis Rheum. 2005 Dec;35(3):185-96. doi: 10.1016/j.semarthrit.2005.06.003. Semin Arthritis Rheum. 2005. PMID: 16325659

5

Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis.

Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA. Singh G, et al. J Rheumatol. 1991 Feb;18(2):188-94. J Rheumatol. 1991. PMID: 1673721 Clinical Trial.

6

Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD.

Cannon GW, Holden WL, Juhaeri J, Dai W, Scarazzini L, Stang P. Cannon GW, et al. J Rheumatol. 2004 Oct;31(10):1906-11. J Rheumatol. 2004. PMID: 15468352

7

Patient preferences for treatment of rheumatoid arthritis.

Fraenkel L, Bogardus ST, Concato J, Felson DT, Wittink DR. Fraenkel L, et al. Ann Rheum Dis. 2004 Nov;63(11):1372-8. doi: 10.1136/ard.2003.019422. Epub 2004 Mar 5. Ann Rheum Dis. 2004. PMID: 15020312 Free PMC article.

8

Pharmacogenomics in rheumatoid arthritis.

Ranganathan P. Ranganathan P. Methods Mol Biol. 2008;448:413-35. doi: 10.1007/978-1-59745-205-2_14. Methods Mol Biol. 2008. PMID: 18370240 Review.

9

Disease-modifying antirheumatic drugs, including methotrexate, gold, sulfasalazine, antimalarials, and D-penicillamine.

Conaghan PG, Brooks P. Conaghan PG, et al. Curr Opin Rheumatol. 1996 May;8(3):176-82. Curr Opin Rheumatol. 1996. PMID: 8796975 Review.

10

Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.

Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, Rischmueller M, James MJ, Hill CL, Caughey GE, Cleland LG. Proudman SM, et al. Semin Arthritis Rheum. 2007 Oct;37(2):99-111. doi: 10.1016/j.semarthrit.2007.02.001. Epub 2007 Mar 27. Semin Arthritis Rheum. 2007. PMID: 17391739 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

412 results

Results by year